Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOK OTCMKTS:GNBT NASDAQ:IMMP NASDAQ:JAGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsGNBTGenerex Biotechnology$0.00$0.00▼$0.16$73K-0.0760,924 shsN/AIMMPPrima BioMed$0.49+1.2%$0.49$0.29▼$3.53$71.61M2.241.12 million shs357,230 shsJAGXJaguar Animal Health$2.91-16.1%$10.82$2.53▼$171.50$1.08M0.01147,954 shs121,713 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%0.00%0.00%0.00%+218.84%GNBTGenerex Biotechnology0.00%0.00%0.00%0.00%0.00%IMMPPrima BioMed+1.17%-6.50%-17.99%-82.58%-74.95%JAGXJaguar Animal Health-16.14%-25.77%-79.71%-86.35%-98.05%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$11.00+0.4%$10.90$2.28▼$11.00$18.92M-0.15983,927 shs47,100 shsGNBTGenerex Biotechnology$0.00$0.00▼$0.16$73K-0.0760,924 shsN/AIMMPPrima BioMed$0.49+1.2%$0.49$0.29▼$3.53$71.61M2.241.12 million shs357,230 shsJAGXJaguar Animal Health$2.91-16.1%$10.82$2.53▼$171.50$1.08M0.01147,954 shs121,713 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%0.00%0.00%0.00%+218.84%GNBTGenerex Biotechnology0.00%0.00%0.00%0.00%0.00%IMMPPrima BioMed+1.17%-6.50%-17.99%-82.58%-74.95%JAGXJaguar Animal Health-16.14%-25.77%-79.71%-86.35%-98.05%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 1.50ReduceN/AN/AGNBTGenerex Biotechnology 0.00N/AN/AN/AIMMPPrima BioMed 1.75Reduce$5.501,031.92% UpsideJAGXJaguar Animal Health 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest EVOK, IMMP, GNBT, and JAGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026JAGXJaguar Animal Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/13/2026IMMPPrima BioMed Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold3/13/2026IMMPPrima BioMed Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Neutral$7.00 ➝ $1.003/13/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/23/2026IMMPPrima BioMed Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageMarket Outperform$10.00(Data available from 5/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$10.25M1.85N/AN/A$4.74 per share2.32GNBTGenerex Biotechnology$2.66M0.00N/AN/AN/ANaNIMMPPrima BioMed$4.08M17.55N/AN/A$0.63 per share0.77JAGXJaguar Animal Health$11.51M0.09N/AN/A($42.30) per share-0.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$5.35M-$2.07N/AN/AN/A-36.23%-101.40%-31.86%N/AGNBTGenerex Biotechnology-$33.33MN/AN/AN/AN/AN/AN/AN/AN/AIMMPPrima BioMed-$39.78MN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar Animal Health-$53.43M-$1,162.24N/AN/AN/A-169.04%-1,194.94%-115.55%N/ALatest EVOK, IMMP, GNBT, and JAGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026JAGXJaguar Animal Health-$149.10-$13.60+$135.50-$13.60$4.21 million$20.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/AGNBTGenerex BiotechnologyN/AN/AN/AN/AN/AIMMPPrima BioMedN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.271.22GNBTGenerex BiotechnologyN/AN/AN/AIMMPPrima BioMedN/A2.97N/AJAGXJaguar Animal Health4.080.500.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/AGNBTGenerex BiotechnologyN/AIMMPPrima BioMed2.32%JAGXJaguar Animal Health12.04%Insider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%GNBTGenerex Biotechnology35.20%IMMPPrima BioMed3.07%JAGXJaguar Animal Health2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.72 million1.68 millionNot OptionableGNBTGenerex Biotechnology15122.06 million79.09 millionNot OptionableIMMPPrima BioMed2,021147.37 million142.85 millionOptionableJAGXJaguar Animal Health50372,000364,000No DataEVOK, IMMP, GNBT, and JAGX HeadlinesRecent News About These CompaniesJaguar Animal Health (NASDAQ:JAGX) Upgraded to Hold at Wall Street ZenMay 23 at 1:13 AM | americanbankingnews.comJaguar Health (JAGX) Q3 2025 Earnings TranscriptMay 22 at 9:45 AM | aol.comAJaguar Health Reports First Quarter 2026 FinancialsMay 20 at 4:40 PM | accessnewswire.comAJaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor ConferenceMay 20 at 9:00 AM | accessnewswire.comAJaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral CrofelemerMay 19, 2026 | accessnewswire.comAJaguar Animal Health Granted Short Nasdaq Compliance ExtensionMay 16, 2026 | theglobeandmail.comJaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price RuleMay 8, 2026 | accessnewswire.comAJaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)May 6, 2026 | accessnewswire.comAJaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut HealthMay 4, 2026 | accessnewswire.comAJaguar Health, Inc.: Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea in DogsApril 30, 2026 | finanznachrichten.deJaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in DogsApril 29, 2026 | accessnewswire.comAJaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock SplitApril 27, 2026 | accessnewswire.comAJaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for ...April 24, 2026 | usatoday.comJaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of StockholdersApril 20, 2026 | accessnewswire.comAArtificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) ProgramsApril 13, 2026 | accessnewswire.comAJaguar Health, Inc. (JAGX) Q4 2025 Earnings Call Prepared Remarks TranscriptApril 10, 2026 | seekingalpha.comReminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company UpdatesApril 9, 2026 | accessnewswire.comAJaguar Health Reports 2025 FinancialsApril 7, 2026 | accessnewswire.comAJaguar Health Inc.April 4, 2026 | barrons.comJaguar Health Delays Annual Form 10-K FilingApril 4, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEVOK, IMMP, GNBT, and JAGX Company DescriptionsEvoke Pharma NASDAQ:EVOKEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Generex Biotechnology OTCMKTS:GNBTGenerex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.Prima BioMed NASDAQ:IMMP$0.49 +0.01 (+1.17%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.48 0.00 (-1.01%) As of 05/22/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Jaguar Animal Health NASDAQ:JAGX$2.91 -0.56 (-16.14%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.05 +0.14 (+4.78%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
